Skip to main content
. 2023 May 22;44(31):2893–2907. doi: 10.1093/eurheartj/ehad347

Figure 2.

Figure 2

Kaplan–Meier curves comparing survival in patients treated with ACEi/ARBs to patients not treated with ACEi/ARBs followed by a Cox proportional hazards regression analysis: (A) treatment with ACEi/ARBs vs. no treatment with ACEi/ARBs in the overall population, (B) treatment with ACEi/ARBs vs. no treatment with ACEi/ARBs in patients with a LVEF ≤40%, (C) treatment with ACEi/ARBs vs. no treatment with ACEi/ARBs in patients with a LVEF >40%